TCL1A
T-cell leukemia/lymphoma protein 1A
Also known as: TCL1, TCL1A_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P56279
- Gene
- TCL1A
- Ensembl
- ENSG00000100721
- Chromosome
- 14
- Canonical length
- 114 aa
- Protein class
- Cancer-related genes, Disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Endoplasmic reticulum,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Overexpression of the TCL1 gene in humans has been implicated in the development of mature T cell leukemia, in which chromosomal rearrangements bring the TCL1 gene in close proximity to the T-cell antigen receptor (TCR)-alpha (MIM 186880) or TCR-beta (MIM 186930) regulatory elements (summarized by Virgilio et al., 1998 [PubMed 9520462]). In normal T cells TCL1 is expressed in CD4-/CD8- cells, but not in cells at later stages of differentiation. TCL1 functions as a coactivator of the cell survival kinase AKT (MIM 164730) (Laine et al., 2000 [PubMed 10983986]).[supplied by OMIM, Jul 2010]
Canonical amino-acid sequenceUniProt
114 residues, UniProt reviewed canonical sequence.
>P56279|TCL1A
1 MAECPTLGEA VTDHPDRLWA WEKFVYLDEK QHAWLPLTIE IKDRLQLRVL LRREDVVLGR
61 PMTPTQIGPS LLPIMWQLYP DGRYRSSDSS FWRLVYHIKI DGVEDMLLEL LPDDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TCL1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 250 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 250 nTPM
- tonsil: 202 nTPM
- spleen: 53 nTPM
- appendix: 32 nTPM
- bone marrow: 19 nTPM
- thymus: 18 nTPM
Single-cell type
- pdcs: 736 nCPM
- b-cells: 170 nCPM
- oocytes: 120 nCPM
- differentiating spermatogonia: 59 nCPM
- early primary spermatocytes: 59 nCPM
- thymocytes: 14 nCPM
Immune cell
- naive B-cell: 2,165 nTPM
- plasmacytoid DC: 1,103 nTPM
- memory B-cell: 880 nTPM
- total PBMC: 92 nTPM
- basophil: 4.6 nTPM
- neutrophil: 3.3 nTPM
Brain region
- white matter: 0.8 nTPM
- basal ganglia: 0.6 nTPM
- cerebral cortex: 0.6 nTPM
- hypothalamus: 0.6 nTPM
- medulla oblongata: 0.6 nTPM
- midbrain: 0.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.92
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.32
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TCL1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TCL1A as an antibody target. Whether an autoantibody or antibody against TCL1A could matter depends on whether native TCL1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TCL1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TCL1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...